A comparison of the inhibitory effect of nano-encapsulated helenalin and free helenalin on telomerase gene expression in the breast cancer cell line, by real-time PCR

Kordi, Shirafkan; Zarghami, Nosratollah; Akbarzadeh, Abolfazl; Rahmati, Yamchi Mohammad; Ghasemali, Somaye; Barkhordari, Amin; Tozihi, Majid

doi:10.3109/21691401.2014.981270

Cited by 9 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently most epidemiological studies show that many breast cancer patients are using alternative medicines that mostly have an herbal origin. Additionally, these studies suggest that a preclinical study is critical to confirm the efficacy of Helenalin chemotherapy in the human breast cancer in an in vivo model (Ghasemali et al, 2013;Kordi et al, 2016); The preclinical data presented here show significant therapeutic effect of Helenalin in these in vitro models of breast cancer (EL et al, 1995). With a favorable side effect profile and long history of human use, Helenalin represents a good candidate for treatment.…”

Section: Discussionmentioning

confidence: 66%

Potential Anti-Cancer Effect of Helenalin as a Natural Bioactive Compound on the Growth and Telomerase Gene Expression in Breast Cancer Cell Line

Barkhordari¹,

Jafari-Gharabaghlou

Türk

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective:The telomerase gene is overexpressed in the majority of tumors and cancers compared to normal and healthy cells, and on the other hand, this enzymatic protein is overactive, therefore, the telomerase enzyme is considered a primary target for diagnostic and therapeutic purposes in most cancers. This has been hypothesized that Helenalin has anti-telomerase activity in a wide range of cancers and Tumor tissues. In this study, we investigated the inhibitory effect of helenalin extract on telomerase gene expression in the T47D breast cancer cell line. Methods: We used the MTT assay to evaluate the cytotoxic effect of different concentrations of helenalin on the T47D breast cancer cell line at 24, 48, and 72 hours. Besides, the expression of the hTERT gene in T47D cell lines treated with 1.0 and 5.0 µM helenalin after 24, 48, and 72 h incubation times was investigated through real-time PCR. Results: According to the MTT assay, the inhibitory effect of helenalin on T47D cell proliferation is time and dose-dependent. Moreover, the results of Real-time PCR showed that exposure of T47D cell lines to helenalin led to a significant Decreasing in the expressional values of the hTERT gene as a time and dose-dependent procedure compared with the control group (P ≤ 0.05). Conclusion: These preliminary results demonstrated the cytotoxic potential of helenalin through inhibition of hTERT against T47D breast cancer cells.

show abstract

Section: Discussionmentioning

confidence: 66%

Potential Anti-Cancer Effect of Helenalin as a Natural Bioactive Compound on the Growth and Telomerase Gene Expression in Breast Cancer Cell Line

Barkhordari¹,

Jafari-Gharabaghlou

Türk

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Today, there is a growing trend in targeted therapy with nanoparticles. 29,30 Several studies have also shown that the most important fragments of KDR3 for antibody production are the first to the third domains, especially the third domain. 12,13 In the light of previous studies, a segment of the KDR3 was also selected with regard to its accessibility and design for peptide synthesis.…”

Section: Discussionmentioning

confidence: 99%

Isolation of a novel Anti-KDR3 Single-chain Variable Fragment Antibody from a Phage Display Library

Kordi

Rahmati-Yamchi

Vostakolaei

et al. 2019

IJAAI

Self Cite

View full text Add to dashboard Cite

Vascular endothelial growth factor receptor 2 (VEGFR-2) is known as one of the important antigens playing a vital role in angiogenesis. In this study, phage display technology (PDT) was used to produce a single-chain variable fragment (scFv) antibody against a region of the domain 3 in VEGFR-2 called kinase insert domain receptor 3 (KDR3). After designing the KDR3 peptide and biopanning, a colony was chosen for scFv antibody expression. Following expression and purification; western blotting, dot blotting and immunofluorescence (IF) were used to evaluate the antibody function. Surface plasmon resonance (SPR) was also employed to measure affinity of produced antibody. Once a colony was selected and transferred to the expression host, the scFv antibody was expressed in the expected range of 28 kDa. Using a designed chromatography column, antibody purification was found to be about 95%. In this study, a novel scFv with the capability of binding to KDR3 was isolated and purified and its intracellular function was investigated and verified.

show abstract

“…Thus, we decided to treat RMS cells with helenalin only for 24 h in the study to find the mechanism of action, since over 95% of the compound persisted for 24 h. A longer time course might be complicated by the degradation of the compound. A previous study investigating the effect of helenalin on breast cancer (T47D) cells exhibited an IC 50 of 1.3 µM after 72 h treatment [21], indicating that helenalin is less cytotoxic to the embryonic RMS cancer (RD) cells than breast cancer cells. We have also tested control fibroblast (non-tumour) cells, which showed IC 50 of 9.26 µM after 24 h incubation, and 5.65 µM after 72 h incubation (Figure S2).…”

Section: Cytotoxicity Of Helenalin Against Rms Cellsmentioning

confidence: 98%

Mechanism of Action of the Sesquiterpene Compound Helenalin in Rhabdomyosarcoma Cells

Mun

Townley

2021

Pharmaceuticals

View full text Add to dashboard Cite

Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in paediatric patients. Relapsed or refractory RMS shows very low 5-year survival rates, which urgently necessitates new chemotherapy agents. Herein, the sesquiterpene lactone, helenalin, was investigated as a new potential therapeutic agent against the embryonal RMS (eRMS) and alveolar RMS (aRMS) cells. We have evaluated in vitro antiproliferative efficacy of helenalin on RMS cells by the MTT and wound healing assay, and estimated several cell death pathways by flow cytometry, confocal microscopy and immunoblotting. It was shown that helenalin was able to increase reactive oxygen species levels, decrease mitochondrial membrane potential, trigger endoplasmic reticulum stress and deactivate the NF-κB pathway. Confirmation was obtained through the use of antagonistic compounds which alleviated the effects of helenalin in the corresponding pathways. Our findings demonstrate that oxidative stress is the pivotal mechanism of action of helenalin in promoting RMS cell death in vitro.

show abstract

A comparison of the inhibitory effect of nano-encapsulated helenalin and free helenalin on telomerase gene expression in the breast cancer cell line, by real-time PCR

Abstract: In this study, we demonstrated that the NC-helenalin complex is more effective than free helenalin in inhibiting the growth of breast cancer cells.

Cited by 9 publications

References 48 publications

Potential Anti-Cancer Effect of Helenalin as a Natural Bioactive Compound on the Growth and Telomerase Gene Expression in Breast Cancer Cell Line

Potential Anti-Cancer Effect of Helenalin as a Natural Bioactive Compound on the Growth and Telomerase Gene Expression in Breast Cancer Cell Line

Isolation of a novel Anti-KDR3 Single-chain Variable Fragment Antibody from a Phage Display Library

Mechanism of Action of the Sesquiterpene Compound Helenalin in Rhabdomyosarcoma Cells

Contact Info

Product

Resources

About